证券代码：601567 证券简称：三星医疗 公告编号：临2025-068 宁波三星医疗电气股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月8日 ? 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系统 一、 召开会议的基本情况 (一)股东会类型和届次 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 8 日 14 点 00 分 召开地点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 25 楼会 议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 8 日 至2025 年 9 月 8 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9 ...

8月21日，硬科技宽基"小霸王"——双创龙头ETF（588330）场内价格盘中涨超1.5%，现涨1%，上探2022年3月以来的高点，实时成交额超2900万元，交投 较为活跃，基金最新规模为10.73亿元。 成份股方面，蓝思科技涨超9%，联影医疗、迈瑞医疗、寒武纪涨逾3%，石头科技、江波龙、中航成飞等个股跟涨。 消息面上，8月15日国家统计局数据显示7月高技术制造业增加值同比增长9.3%，集成电路制造增长26.9%，印证硬科技产业链景气度；同期美国云厂商上调 资本开支指引，谷歌2025年资本开支增至850亿美元，Meta指引2026年维持高投入，带动算力需求预期升温。 东方证券指出，科技板块或是确定性主线，尤其看好国内人工智能产业链。AI服务器、数据中心等场景推动PCB性能升级，新一代电子布和石英玻纤成为增 量机会，国产替代空间显现。AI应用领域量变积累质变，模型新版本发布将催化板块反弹。算力产业链中，液冷技术渗透率及价值量有望提升，国产算力 配置刚起步，先进制程产能支撑国产化进程。军工领域关注AI与无人技术结合，机器人聚焦新零部件及细分场景。此外，北美AI基建能源短板凸显，固体 氧化物燃料电池（SOFC）国内 ...

Group 1 - The core viewpoint highlights the strong performance of the "Double Innovation Leading ETF" (588330), which has seen a price increase of over 1.5% and a trading volume exceeding 29 million yuan, indicating active market engagement [1] - The ETF's latest scale is reported at 1.073 billion yuan, reflecting significant investor interest in hard technology sectors [1] - Key constituent stocks such as Lens Technology and Mindray Medical have shown notable gains, with Lens Technology rising over 9% [1] Group 2 - Data from the National Bureau of Statistics indicates that the high-tech manufacturing sector's added value grew by 9.3% year-on-year in July, with integrated circuit manufacturing increasing by 26.9%, suggesting a robust hard technology industry [3] - The technology sector is viewed as a key investment theme, particularly the domestic artificial intelligence industry chain, which is expected to benefit from advancements in AI applications and infrastructure [3] - The report emphasizes the importance of new production capabilities and the potential for excess returns in innovation-driven companies, with a focus on sectors like AI, innovative pharmaceuticals, and robotics [4] Group 3 - The "Double Innovation Leading ETF" is characterized by its cross-market diversification, focusing entirely on strategic emerging industries, including new energy and semiconductors [5] - The ETF is positioned as a high-elasticity tool for capturing technology market trends, with a low investment threshold allowing access to top-tier technology stocks [5] - The index underlying the ETF is designed to reflect the performance of the top 50 strategic emerging companies, enhancing its appeal as a "Chinese version of NASDAQ" [5]

Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [31][32] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [12][32] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [34] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [32] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [32] Market Data and Key Metrics Changes - The company treated 22 million patients with its products during FY 2025 [28] - The manufacturing facility in China became fully operational, contributing to product shipments [29] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years [6][7] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [7] - The company aims to double its constant currency revenue every five to six years sustainably [57] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term approach to mitigate cost increases [8][11] - The outlook for FY 2026 includes revenue expectations between $2,150,000,000 and $2,250,000, with net profit after tax projected between $390,000,000 and $440,000,000 [53] Other Important Information - The board approved a dividend of $0.0425 per share, a 2% increase over the previous year, with a payout ratio of approximately 66% [12][13] - The company is committed to ongoing investments in R&D and maintaining a prudent balance sheet [13] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [63] Question: What are the expectations for FY 2026 underlying profit? - The company provided specific guidance for FY 2026, indicating a long-term growth trajectory despite anomalies during the COVID period [65] Question: Why hasn't the company disclosed proxy votes early? - The company prefers to have discussions without the influence of proxy votes and will disclose them after the meeting [76]

Group 1 - The 2025 Osaka World Expo will be held from April 13 to October 13, 2025, with a theme of "Creating a Future Society that Shines" and will attract participation from 158 countries and regions, along with 7 international organizations [1] - The China Pavilion will focus on "Building a Community of Life between Man and Nature - A Future Society of Green Development," covering an area of approximately 3,500 square meters [1] - The "Liaoning Activity Week" will showcase Liaoning's strengths in technology, ecology, green development, and cultural heritage, aiming to enhance its position as a hub for high-quality cultural and tourism integration and Northeast Asia cooperation [1] Group 2 - A series of activities during the "Liaoning Activity Week" will include an opening ceremony, economic and cultural exchange activities, product showcases, and performances, highlighting Liaoning's cultural and economic strengths [2] - The event will feature the promotion of the Niuhe Liang Hongshan Cultural Site, recognized as a significant archaeological site, using advanced holographic technology for display [2] - Innovations in technology will be showcased, including performances by robots from Shenyang Siasun Robot & Automation Co., models of gas turbines from China Aviation Engine Corporation, and digital printing technology from Shenyang Flying Ship Digital Printing Equipment Co., emphasizing Liaoning's technological capabilities [2] Group 3 - The event will also promote the Shenyang Area of the China (Liaoning) Pilot Free Trade Zone and the Shenyang and Fushun Reform and Innovation Demonstration Zone, highlighting the improved business environment and resource advantages in Liaoning [3] - "Dalian Day" will feature a series of activities to showcase Dalian's geographical, industrial, and cultural advantages, as well as its openness and humanistic environment [3] - The Liaoning Provincial Council for the Promotion of International Trade aims to leverage the "Liaoning Activity Week" as a platform for cultural exchange and to expand economic cooperation with neighboring countries and regions [3]

Core Insights - Masimo (MASI) received FDA 510(k) clearance for expanded indications of its O3 Regional Oximetry, which now includes delta hemoglobin parameters to track changes in hemoglobin levels, enhancing the ability to identify causes of tissue oxygen saturation shifts [1][6] - The O3 platform, built on Masimo's Root platform, utilizes near-infrared spectroscopy to measure continuous regional oxygen saturation (rSO2), providing deeper insights into oxygen imbalances and aiding precise clinical interventions [2][7] - The FDA approval broadens the clinical utility of O3 across all patient populations, including pediatrics and neonates, making it more valuable in critical care settings [4][8] Company Performance - Following the FDA announcement, MASI shares declined by 4.6% at market close, with a year-to-date loss of 11.2%, compared to the industry decline of 7.6% and a 9.5% gain in the S&P 500 [3] - Masimo currently has a market capitalization of $8.36 million and reported an earnings surprise of 8.13% in the last quarter [5] Industry Outlook - The FDA clearance is expected to act as a growth catalyst for Masimo by enhancing the adoption of its O3 platform and driving recurring revenue from monitoring solutions, positioning the company to capture a larger share of the high-margin brain and tissue monitoring market [4] - The global cerebral oximetry monitoring market was valued at $239.4 million in 2024 and is projected to grow at a CAGR of 6.7% from 2025 to 2034, driven by the increasing prevalence of neurological ailments and surgeries [10]

Group 1 - The Liaoning Provincial Government will hold the "Liaoning Activity Week" at the China Pavilion of the Osaka World Expo from August 24 to 26 to expand foreign cooperation and exchange channels [1] - The event will showcase Liaoning's comprehensive strengths in technology, ecology, green initiatives, low carbon, and intangible cultural heritage, aiming to enhance interactions with neighboring countries and regions, including Japan [1] - Activities during the event will include product promotions, cultural performances, intangible cultural heritage exhibitions, and a special focus on the Niuhe Liang Hongshan Cultural Site, which is recognized as a representative of the ancient state era [1] Group 2 - Japan is a significant trade partner for Liaoning Province, with ongoing expansion in friendly exchanges and economic cooperation [2] - The Liaoning Provincial Council for the Promotion of International Trade has engaged with important Japanese business associations and enterprises to deepen trade cooperation and local industry collaboration [2] - The event aims to provide a platform for Japanese stakeholders to better understand Liaoning's resource endowments, location, and environmental advantages, thereby attracting more Japanese investment [2]

Core Viewpoint - The Liaoning Provincial Government will host the "Liaoning Activity Week" at the China Pavilion during the Osaka Expo from August 24 to 26, aiming to expand foreign cooperation and exchange channels [1][2]. Group 1: Event Overview - The "Liaoning Activity Week" will showcase the province's strengths in technology, ecology, green initiatives, low carbon, and intangible cultural heritage [1]. - A series of activities will be held, including product promotions, cultural performances, intangible cultural heritage exhibitions, and a special day for Dalian [1]. - The event will prominently feature the Niuhe Liang Hongshan Cultural Site, recognized as a representative of the early stage of ancient state civilization [1]. Group 2: Technological Innovations - The event will demonstrate achievements in technological innovation, including live calligraphy performances by robots and models of the "Taihang 110" gas turbine from China Aviation Engine Corporation [1]. - Other showcased technologies include a CT machine model from Neusoft Group and a digital printing technology from Shenyang Flying Ship Digital Printing Equipment Co., Ltd. [1]. Group 3: Trade Relations - Japan is identified as an important trade partner for Liaoning Province, with ongoing expansion in friendly exchanges and economic cooperation [2]. - The Liaoning Provincial Council for the Promotion of International Trade has engaged with Japanese business associations and enterprises to deepen trade cooperation and local industry collaboration [2]. - The event aims to provide a direct experience of Liaoning's resource endowments, location, and environmental advantages to attract more Japanese investment [2].

Group 1 - The stock price of Shangrong Medical as of August 20, 2025, is 4.95 yuan, down 0.25 yuan from the previous trading day [1] - The opening price on the same day was 5.13 yuan, with a high of 5.13 yuan and a low of 4.88 yuan, and total trading volume reached 1.118 million hands with a transaction amount of 556 million yuan [1] - On August 20, around 9:40 AM, the stock price experienced a rapid rebound, increasing over 2% within 5 minutes, with a transaction amount of 139 million yuan [1] Group 2 - Shangrong Medical's main business includes the design, research and development, production, and sales of medical equipment and medical system engineering [1] - The company's product range covers medical oxygen systems, medical gas engineering, and clean surgical departments in hospitals [1] Group 3 - On August 20, the net outflow of main funds was 35.3587 million yuan, accounting for 1.17% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 10.9190 million yuan [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million yuan, representing a year-on-year growth of 28.69%, and a net profit attributable to the parent company of 39.32 million yuan, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Activity - On August 20, the company's stock price increased by 0.11%, with a trading volume of 212 million yuan and a turnover rate of 12.93%, resulting in a total market capitalization of 12.087 billion yuan [1]. - The main net inflow of funds today was 8.9166 million yuan, accounting for 0.04%, with the industry ranking at 9 out of 131 [4]. Product and Technology Development - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pet, equine, and livestock health care [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR equipment, enabling remote transmission of images and reports through 5G networks, and offers online diagnostic guidance through the "Mali Doctor" platform [2][3].